We Accept amex

Formerly known as Maylips.com

info@directdoctorsupply.com+1-800-325-7104

Logo Logo
Track delivery Wishlist
  • 0 $ 0.00
  • Products
    • All Products
    • Peptides NEW
    • Anaesthetics
    • Body Sculpting
    • Botulinum Toxin
    • Cannulas and Needles
    • Cellular Rejuvenation
    • Dermal Filler Removal
    • Dermal Fillers
      • Biostimulators
      • HA Dermal Fillers
      • Korean Dermal Fillers
      • Polynucleotides
      • Skinboosters
    • Exosomes
    • Eyelash Enhancers
    • Fat Removal
    • Gynecology
    • Mesotherapy
    • IV Therapy
    • Orthopedic Injections
    • Peels and Masks
    • PRP Kits
    • Skincare
    • Threads
      • PCLA Threads
      • PDO Threads
      • PLA Threads
    • Weight Loss
  • Brands
    • ALIAXIN®
    • ALIDYA™
    • AQUALYX®
    • AZZALURE®
    • BCN
    • BELLAST®
    • BELOTERO®
    • BIOREPEELCL3®
    • BOCOUTURE® (XEOMIN®)
    • BOTOX®
    • CAREGEN
    • CINGAL®
    • CRESPINE®
    • CROMA
    • CYTOCARE
    • DEPO-PROVERA®
    • DERMALAX™
    • DESIRIAL®
    • DUROLANE®
    • DYSPORT®
    • EJAL
    • ELLANSÉ™
    • EMLA™
    • Euflexxa
    • FILLMED®
    • FILORGA®
    • GARDASIL®
    • HArmonyCA™
    • HYACORP
    • HYAFILIA®
    • HYALGAN®
    • HYMOVIS®
    • HYNIDASE®
    • INTRALINE®
    • JALUPRO®
    • JAYDESS®
    • JUVÉDERM®
    • KARISMA
    • LEMONBOTTLE
    • LANLUMA
    • LIPORASE®
    • MEDIDERMA®
    • MESO-RELLE®
    • MESOESTETIC®
    • MICRONJET™
    • MIRENA®
    • MONOVISC®
    • MOUNJARO®
    • NEAUVIA™
    • NEURAMIS®
    • NEXPLANON®
    • NITHYA
    • NOVERA COMPOUNDS
    • NUCLEOFILL™
    • ORTHOVISC®
    • OZEMPIC®
    • PERFECTHA®
    • PLASMOLIFTING™
    • PROFHILO®
    • ​PROSTROLANE®
    • PRX-T33®
    • RADIESSE®
    • RAINBOW
    • REFINE
    • REJURAN®
    • REJUVANAD+
    • REFINE
    • RESTYLANE®
    • REVANESSE®
    • REVOFIL
    • REVOLAX™
    • SAXENDA®
    • SAYPHA®
    • SCULPTRA®
    • SESDERMA®
    • SILHOUETTE
    • SMB®
    • SOFTFIL®
    • STYLAGE®
    • SUNEKOS®
    • SUPARTZ®
    • SYNVISC®
    • T-SAFE®
    • TEOSYAL®
    • ​THERASET®
    • VISCODERM®
    • WEGOVY®
    • XEOMIN®
    • ZO®
  • Peptides NEW
  • Sale
  • Shipping
  • Contact
  • About Us
  • Referral Program
  • Blog
  • Sign In / Register
Logo Logo
Menu
Close
Wishlist
  • Products
    • All Products
    • Peptides NEW
    • Anaesthetics
    • Body Sculpting
    • Botulinum Toxin
    • Cannulas and Needles
    • Cellular Rejuvenation
    • Dermal Filler Removal
    • Dermal Fillers
      • Biostimulators
      • HA Dermal Fillers
      • Korean Dermal Fillers
      • Polynucleotides
      • Skinboosters
    • Exosomes
    • Eyelash Enhancers
    • Fat Removal
    • Gynecology
    • Mesotherapy
    • IV Therapy
    • Orthopedic Injections
    • Peels and Masks
    • PRP Kits
    • Skincare
    • Threads
      • PCLA Threads
      • PDO Threads
      • PLA Threads
    • Weight Loss
  • Brands
    • ALIAXIN®
    • ALIDYA™
    • AQUALYX®
    • AZZALURE®
    • BCN
    • BELLAST®
    • BELOTERO®
    • BIOREPEELCL3®
    • BOCOUTURE® (XEOMIN®)
    • BOTOX®
    • BOTULAX®
    • CAREGEN
    • CINGAL®
    • CRESPINE®
    • CROMA
    • CYTOCARE
    • DEPO-PROVERA®
    • DERMALAX™
    • DESIRIAL®
    • DUROLANE®
    • DYSPORT®
    • EJAL
    • ELLANSÉ™
    • EMLA™
    • Euflexxa
    • FILLMED®
    • FILORGA®
    • GARDASIL®
    • HArmonyCA™
    • HYACORP
    • HYAFILIA®
    • HYALGAN®
    • HYMOVIS®
    • HYNIDASE®
    • INNOTOX®
    • INTRALINE®
    • JALUPRO®
    • JAYDESS®
    • JUVÉDERM®
    • KAIMAX
    • KARISMA
    • LEMONBOTTLE
    • LETYBO®
    • LANLUMA
    • LIPORASE®
    • LIZTOX®
    • MEDIDERMA®
    • MEDITOXIN®
    • MESO-RELLE®
    • MESOESTETIC®
    • MICRONJET™
    • MIRENA®
    • MONOVISC®
    • MOUNJARO®
    • NABOTA® (JEUVEAU®)
    • NEAUVIA™
    • NEURAMIS®
    • NEXPLANON®
    • NITHYA
    • NOVERA COMPOUNDS
    • NUCLEOFILL™
    • ORTHOVISC®
    • OZEMPIC®
    • PERFECTHA®
    • PLASMOLIFTING™
    • PROFHILO®
    • ​PROSTROLANE®
    • PRX-T33®
    • RADIESSE®
    • RAINBOW
    • Re N Tox™
    • REFINE
    • REJURAN®
    • REJUVANAD+
    • REFINE
    • RESTYLANE®
    • REVANESSE®
    • REVOFIL
    • REVOLAX™
    • SAXENDA®
    • SAYPHA®
    • SCULPTRA®
    • SESDERMA®
    • SILHOUETTE
    • SMB®
    • SOFTFIL®
    • STYLAGE®
    • SUNEKOS®
    • SUPARTZ®
    • SYNVISC®
    • T-SAFE®
    • TEOSYAL®
    • ​THERASET®
    • VISCODERM®
    • WEGOVY®
    • XEOMIN®
    • ZO®
  • Peptides NEW
  • Sale
  • Shipping
  • Contact
  • About Us
  • Referral Program
  • Blog
  • Sign In / Register
  • 0 $ 0.00
Direct Doctor SupplyPeptides for ResearchWeight Loss & Metabolic PeptidesTirzepatide
Product Category
  • Anaesthetics (2)
  • Body Sculpting (4)
  • Botulinum Toxins (33)
  • Cannulas and Needles (13)
  • Cellular Rejuvenation (1)
  • Dermal Filler Removal (2)
  • Dermal Fillers (192)
  • Biostimulators (10)
  • HA Dermal Fillers (129)
  • Korean Dermal Fillers (28)
  • Polynucleotides (17)
  • Skinboosters (16)
  • Exosomes (1)
  • Eyelash Enhancers (1)
  • Fat Removal (3)
  • Gynecology (8)
  • IV Therapy (2)
  • Mesotherapy (23)
  • Orthopedic Injections (11)
  • Peels and Masks (23)
  • Peptides for Research (45)
  • Aesthetic & Cosmetic Peptides (1)
  • Brain, Cognitive & Nootropic Peptides (4)
  • Healing & Regenerative Peptides (6)
  • Immune & Thymic Peptides (4)
  • Longevity & Anti-Aging Peptides (7)
  • Muscle Growth & Performance Peptides (11)
  • Sexual Health & Hormonal Peptides (3)
  • Weight Loss & Metabolic Peptides (11)
  • PRP Kits (1)
  • Skincare (26)
  • Threads (28)
  • PCLA Threads (3)
  • PDO Threads (20)
  • PLA Threads (3)
  • Weight Loss (24)
Product Brand
  • ALIAXIN® (6)
  • ALIDYA™ (1)
  • AQUALYX® (1)
  • AZZALURE® (1)
  • BCN (12)
  • BELLAST® (3)
  • BELOTERO® (7)
  • BIOMEDICO (3)
  • BIOREPEELCL3® (2)
  • BOCOUTURE® (XEOMIN®) (3)
  • BOTOX® (6)
  • CAREGEN (2)
  • CINGAL® (1)
  • CRESPINE® (1)
  • CROMA (4)
  • CYTOCARE (4)
  • DEPO-PROVERA® (1)
  • DERMALAX™ (3)
  • DESIRIAL® (2)
  • DUROLANE® (1)
  • DYSPORT® (4)
  • EJAL (1)
  • ELLANSÉ™ (2)
  • EMLA™ (2)
  • EUFLEXXA® (1)
  • EXOJUV (1)
  • FILLMED® (14)
  • FILORGA® (2)
  • GARDASIL® (1)
  • HArmonyCA™ (1)
  • HYACORP (5)
  • HYAFILIA® (2)
  • HYALGAN® (1)
  • HYMOVIS® (1)
  • HYNIDASE® (1)
  • INTRALINE® (24)
  • JALUPRO® (5)
  • JAYDESS® (1)
  • JUVÉDERM® (13)
  • KARISMA (1)
  • LANLUMA (1)
  • LEMONBOTTLE (1)
  • LIPORASE® (1)
  • MEDIDERMA® (26)
  • MESO-RELLE® (2)
  • MESOESTETIC® (2)
  • MICRONJET™ (1)
  • MIRENA® (1)
  • MONOVISC® (1)
  • MOUNJARO® (9)
  • NEAUVIA™ (11)
  • NEURAMIS® (1)
  • NEXPLANON® (2)
  • NITHYA (3)
  • NOVERA COMPOUNDS (46)
  • NUCLEOFILL™ (8)
  • ORTHOVISC® (1)
  • OZEMPIC® (8)
  • PERFECTHA® (4)
  • PLASMOLIFTING™ (1)
  • PLINEST® (5)
  • PROFHILO® (3)
  • ​PROSTROLANE® (1)
  • PRX-T33® (1)
  • RADIESSE® (3)
  • RAINBOW (7)
  • REFINE (3)
  • REJURAN® (3)
  • REJUVANAD+ (2)
  • RENEFIL (3)
  • RESTYLANE® (10)
  • REVANESSE® (6)
  • REVOFIL (9)
  • REVOLAX™ (4)
  • SAXENDA® (1)
  • SAYPHA® (6)
  • SCULPTRA® (1)
  • SESDERMA® (10)
  • SILHOUETTE (3)
  • SMB® (1)
  • SOFTFIL® (6)
  • STYLAGE® (25)
  • SUNEKOS® (4)
  • SUPARTZ® (1)
  • SYNVISC® (2)
  • T-SAFE® (1)
  • TEOSYAL® (12)
  • ​THERASET® (1)
  • ULTRA V® (1)
  • VISCODERM® (2)
  • WEGOVY® (6)
  • XEOMEEN® (1)
  • XEOMIN® (4)
  • ZO® (3)

Tirzepatide

Showing all 11 results

Sort By:
  • Tirzepatide 100mg FrontTirzepatide 100mg Back
    Tirzepatide 100mg
    $ 499.00
    Read More
    -+
  • Tirzepatide 10mg FrontTirzepatide 10mg Front Back
    Tirzepatide 10mg
    $ 135.00
    Read More
    -+
  • Coming Soon
    Tirzepatide 120mg FrontTirzepatide 120mg Back
    Tirzepatide 120mg
    Read More
  • Tirzepatide 15mg FrontTirzepatide 15mg Back
    Tirzepatide 15mg
    $ 155.00
    Read More
    -+
  • Tirzepatide 20mg FrontTirzepatide 20mg Back
    Tirzepatide 20mg
    $ 165.00
    Read More
    -+
  • Tirzepatide 30mg FrontTirzepatide 30mg Back
    Tirzepatide 30mg
    $ 189.00
    Read More
    -+
  • Coming Soon
    Tirzepatide 40mg FrontTirzepatide 40mg Back
    Tirzepatide 40mg
    Read More
  • Coming Soon
    Tirzepatide 50mg FrontTirzepatide 50mg Back
    Tirzepatide 50mg
    Read More
  • Tirzepatide 5mg FrontTirzepatide 5mg Back
    Tirzepatide 5mg
    $ 95.00
    Read More
    -+
  • Tirzepatide 60mg FrontTirzepatide 60mg Back
    Tirzepatide 60mg
    $ 339.00
    Read More
    -+
  • Coming Soon
    Tirzepatide 75mg FrontTirzepatide 75mg Back
    Tirzepatide 75mg
    Read More

Tirzepatide is an FDA-approved dual agonist of the GLP-1 and GIP receptors, developed by Eli Lilly and studied extensively for weight reduction and glycemic control. Endocrinologists, obesity medicine specialists, and compounding pharmacists consider it a benchmark agent in the metabolic peptide category. Practitioners seeking sourcing direction and documentation support may contact the Direct Doctor Supply support team, and the guide below reviews mechanism, clinical evidence, dosing references, safety, and regulatory considerations.

What Is Tirzepatide & How Does It Work? GLP-1 & GIP Dual Agonist Mechanism

Tirzepatide is a synthetic peptide developed by Eli Lilly that co-activates the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. It holds FDA approval in the United States under two brand names: Mounjaro for type 2 diabetes mellitus and Zepbound for chronic weight management [3][5]. In Phase 3 trial data, this dual mechanism of action produced the largest mean weight reductions reported among approved incretin-based agents [1], which is why Tirzepatide is often used as the reference point in the weight loss and metabolic peptide category.

What separates Tirzepatide from earlier incretin therapies is that it is a single molecule engaging two receptors at once, rather than acting on the GLP-1 receptor alone. Its activity therefore spans several metabolic pathways simultaneously, including appetite regulation, insulin secretion, energy balance, and lipid handling in adipose tissue.

The GLP-1 receptor pathway contributes to:

  • Appetite suppression
  • Slowed gastric emptying
  • Glucose-dependent insulin secretion
  • Reduced glucagon secretion
  • Improved post-meal control of blood sugar levels

These effects are the same pathway targeted by Semaglutide and other GLP-1 receptor agonists [2].

The GIP receptor component adds a second mechanism that, based on trial and preclinical data, may:

  • Further enhance insulin secretion
  • Improve lipid metabolism in adipose tissue
  • Contribute to greater weight reduction
  • Improve gastrointestinal tolerability

GIP receptor activity is the mechanistic differentiator between Tirzepatide and pure GLP-1 agonists.

On Compounded and Oral Tirzepatide

These are formulations prepared by compounding pharmacies under specific regulatory conditions. These preparations are not equivalent to the FDA-approved branded products and may differ in manufacturing controls, analytical testing, and regulatory oversight [4]. Practitioners comparing sourcing options, including those weighing whether to buy Tirzepatide online, should review purity documentation, batch testing records, and supply chain transparency before making any procurement decision. This applies with particular force when buying online, where the quality of documentation varies considerably between suppliers.

Oral tirzepatide, meanwhile, remains in clinical development. Phase 3 studies are evaluating whether oral delivery can match the efficacy of subcutaneous administration while improving convenience and adherence. It has not received FDA approval and remains investigational; practitioners following the pipeline should verify current approval status directly with the FDA before acting on any development news.

Tirzepatide for Weight Loss: Clinical Evidence & Dosage

The strongest evidence for Tirzepatide comes from the SURMOUNT and SURPASS Phase 3 programs, which enrolled adults with obesity and adults with type 2 diabetes mellitus, respectively.

  • SURMOUNT-1, a Phase 3 randomized controlled trial, evaluated Tirzepatide in adults with obesity or overweight. At 72 weeks, mean body weight reductions were approximately 15.0% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg, all significantly greater than placebo [1].
  • SURPASS-2, a Phase 3 head-to-head randomized trial, compared Tirzepatide directly against Semaglutide in patients with type 2 diabetes mellitus and reported greater HbA1c reduction and greater weight loss with Tirzepatide [2]. This remains the only direct randomized comparison between the two agents.

These outcomes were generated with the approved branded product under trial conditions and cannot be assumed to transfer to compounded or research-grade preparations.

Tirzepatide Dosage and Administration

  • Weeks 1 to 4: 2.5 mg once weekly
  • Weeks 5 to 8: 5 mg once weekly
  • Subsequent increases of 2.5 mg at intervals of no less than 4 weeks, as tolerated
  • Maximum approved maintenance dose: 15 mg once weekly

Note: These figures are drawn from FDA-approved prescribing information and are reproduced as a label-derived reference, not as prescribing guidance [3].

Administration is by subcutaneous injection once weekly, into the abdomen, thigh, or upper arm, with sites rotated each week [3].

Label guidance also addresses two practical points practitioners are frequently asked about. If more than 4 days have elapsed since a missed dose, the label directs patients to skip the missed dose and resume the next scheduled dose. Approved injection pens may be stored refrigerated at 2 to 8°C or at room temperature up to 30°C for up to 21 days [3]. Diet and increased physical activity are specified as required adjuncts in the approved labeling, not optional additions [3].

Is Tirzepatide Safe? Side Effects, Warnings & Legal Status

Within the SURMOUNT and SURPASS Phase 3 programs, the safety profile of Tirzepatide was consistent with other incretin-based therapies. Most adverse events reported in those trials were mild to moderate and clustered during dose escalation [1][2]. These findings describe trial populations and should not be read as a prediction of individual outcomes.

Gastrointestinal effects are the most frequently reported adverse events in Phase 3 data, typically peaking during titration [1]:

  • Nausea, most common during dose increases
  • Vomiting, often alongside nausea early in treatment
  • Diarrhea, frequently reported during the titration phase
  • Constipation
  • Abdominal discomfort, including bloating and cramping

Some speculate that Tirzepatide causes hair loss, but discussions attribute reported shedding to telogen effluvium secondary to rapid weight reduction rather than to a direct pharmacologic effect. Comparable observations have been described following bariatric surgery and other substantial weight-loss interventions, with shedding generally resolving as weight stabilizes. This mechanism is an interpretation of reported cases, not an established finding from a controlled trial.

The approved labeling carries a boxed warning referencing thyroid C-cell tumors observed in rodent studies, and a causal relationship for medullary thyroid cancer in humans has not been established. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Symptoms such as swelling in your neck, persistent hoarseness, or difficulty swallowing should be reported to a care provider without delay [3]. Pancreatitis is the second recognized class-level risk across incretin therapies, and persistent abdominal pain warrants prompt evaluation [3].

Regulatory Status

Tirzepatide is approved in the United States by the Food and Drug Administration as Mounjaro for type 2 diabetes mellitus and as Zepbound for chronic weight management [3]. Both are prescription-only medications. Approval status in other jurisdictions differs and should be verified locally.

The FDA’s shortage-list designation for Tirzepatide has changed, which in turn affects the conditions under which compounded versions may be prepared [4]. Compounding eligibility is a moving target: practitioners should verify current federal and state requirements, including 503A and 503B status, before any procurement or prescribing decision.

Reporting to date indicates Tirzepatide is not listed on the World Anti-Doping Agency (WADA) Prohibited List. Athletes and the clinicians advising them should confirm current WADA status directly, as the list is revised annually.

Tirzepatide vs Semaglutide & Retatrutide

Receptor coverage, evidence base, and approval status are the three axes that separate Tirzepatide from its closest comparators.

Tirzepatide vs Semaglutide

Tirzepatide activates both GLP-1 and GIP receptors. Semaglutide, approved as Ozempic, Wegovy, and Rybelsus, acts through the GLP-1 receptor alone. The GIP component is the mechanistic differentiator, and trial data suggest it contributes additional insulin secretion, improved adipose lipid metabolism, and potentially better gastrointestinal tolerability.

SURPASS-2 provides direct head-to-head evidence that Tirzepatide produced greater reductions in HbA1c and weight loss than Semaglutide in patients with type 2 diabetes mellitus [2].

The often-cited contrast between SURMOUNT-1 (approximately 22.5%) and STEP-1 (approximately 15%) is an indirect cross-trial comparison. The two trials used different designs, enrolled different populations, and were not run against one another. The figures should not be treated as an efficacy ranking.

Both agents are FDA-approved, and the choice is clinical rather than a ranking. Practitioners who determine that a longer post-approval record, an oral formulation, or a different tolerability profile better fits the case may buy Semaglutide through a verified research-grade supplier.

Tirzepatide vs Retatrutide

Retatrutide extends the mechanism further by adding glucagon receptor activation alongside GLP-1 and GIP, creating a triple-agonist profile. That third pathway is proposed to increase energy expenditure and reduce liver fat.

Phase 2 data showed weight reductions approaching 24% at the highest dose evaluated. Retatrutide is investigational and currently in Phase 3 (TRIUMPH). Comparing this Phase 2 result against Tirzepatide’s Phase 3 SURMOUNT-1 outcome is an indirect comparison across different trial phases, designs, and populations, and no head-to-head RCT exists. Phase 2 results frequently do not replicate at Phase 3 scale.

That trade-off, approved standard against investigational efficacy, is the decision facing practitioners. Tirzepatide carries FDA approval, a validated dosing protocol, and Phase 3 safety data. Before practitioners commit to a triple-agonist protocol, those weighing whether to buy Retatrutide for investigational evaluation should recognize that it does not yet carry any of those three.

Sourcing Standards for Licensed Practitioners

Tirzepatide sourcing is a decision for qualified licensed professionals only. It is not appropriate for general consumer purchase, and any supplier presenting it that way should be treated as a signal of weak compliance controls.

Whether a practitioner is evaluating a single vial or looking to buy Tirzepatide wholesale, the documentation standard remains the same. Verified research-grade suppliers should be able to produce:

  • Verifiable purity documentation for the specific batch
  • LOT number traceability from manufacture through delivery
  • A certificate of analysis matched to the LOT in hand, not a generic sample

Practitioners seeking guidance on where to buy Tirzepatide, how to order Tirzepatide through a verified research-grade supplier, or how to assess a supplier’s documentation may contact the Direct Doctor Supply support team for sourcing guidance and documentation support.

FAQs

What is Tirzepatide: Mounjaro vs Zepbound?

Tirzepatide is an FDA-approved GLP-1 and GIP dual agonist developed by Eli Lilly. Mounjaro is approved for type 2 diabetes mellitus and Zepbound for chronic weight management. Compounded tirzepatide is not equivalent to either branded formulation, as manufacturing and regulatory standards differ.

How does Tirzepatide work?

Tirzepatide co-activates the GLP-1 and GIP receptors. GLP-1 activity suppresses appetite, slows gastric emptying, and promotes glucose-dependent insulin secretion, while GIP activity also affects adipose tissue and insulin regulation. Phase 3 data show this dual mechanism produces greater weight reduction than GLP-1 agonism alone.

What is the Tirzepatide dosage and where to inject?

Approved labeling begins at 2.5 mg once weekly, escalating in 2.5 mg steps at intervals of at least four weeks to a maintenance range of 5 to 15 mg. Administration is subcutaneous, into the abdomen, thigh, or upper arm, with sites rotated weekly. These figures are label-derived and are not prescribing guidance.

Is Tirzepatide safe: what are the side effects?

Phase 3 trial data describe gastrointestinal effects as the most common adverse events, including nausea, vomiting, diarrhea, and constipation, typically peaking during titration. The label carries a boxed warning for medullary thyroid cancer based on rodent data, with contraindications for personal or family history of MTC or MEN2. Pancreatitis is a recognized class-level risk.

How does Tirzepatide compare to Semaglutide?

Tirzepatide activates GLP-1 and GIP receptors; Semaglutide targets GLP-1 alone. SURPASS-2 is the only direct randomized comparison between the two agents, and it reported greater weight loss and HbA1c reduction with Tirzepatide. Both are FDA-approved, and comparisons drawn between separate trials such as SURMOUNT-1 and STEP-1 are indirect.

What is compounded Tirzepatide and is it still available?

Compounded tirzepatide refers to pharmacy-prepared formulations that are distinct from the branded products. Compounding conditions changed following the FDA’s revision of Tirzepatide’s shortage-list status. Practitioners should verify current federal and state compounding eligibility before any procurement decision.

Citations

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:1056/NEJMoa2206038
  2. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:1056/NEJMoa2107519
  3. US Food and Drug Administration. FDA approves new medication for chronic weight management. 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  4. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  5. Eli Lilly and Company. FDA approves Lilly’s Zepbound (tirzepatide) for chronic weight management. 2023. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight

All content on this website is intended for informational purposes and does not constitute medical advice.

Content prepared by Direct Doctor Supply’s editorial team.

Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.

SVG Logo Color cropped

info@directdoctorsupply.com

+1-800-325-7104

Book a MeetingTrack delivery
Trustpilot

Supported payment providers

Visa Mastercard American Express Google Pay Apple Pay

*Apple Pay and Google Pay are available via a personalized link provided by your account manager.

🔒 Transactions on this website meet strict PCI DSS compliance for your safety.

Product authenticity guaranteed: all products are sourced from licensed distributors and traceable by LOT number.

Company
  • About Us
  • FAQ
  • Contact Us
  • Referral Program
  • Sitemap
Follow Us
  • Facebook
  • Instagram
  • LinkedIn
Company
  • About Us
  • FAQ
  • Contact Us
  • Referral Program
Follow Us
  • Facebook
  • Instagram
  • Linkedin
Products
  • Anaesthetics
  • Body Sculpting
  • Botulinum Toxin
  • Needles and Cannula
  • Filler Removal
  • Dermal Fillers
  • Eyelash Enhancers
  • Fat Removal
  • Gynecology
  • Mesotherapy
  • Orthopaedic Injections
  • Peels and Masks
  • PRP Kits
  • Skincare
  • Threads
  • Weight Management
Products
  • Anaesthetics
  • Body Sculpting
  • Botulinum Toxin
  • Needles and Cannula
  • Filler Removal
  • Dermal Fillers
  • Eyelash Enhancers
  • Fat Removal
  • Gynecology
  • Mesotherapy
  • Orthopaedic Injections
  • Peels and Masks
  • PRP Kits
  • Skincare
  • Threads
  • Weight Management

All peptide products sold by Direct Doctor Supply are Research Use Only (RUO) and intended solely for laboratory and scientific research. They are not FDA-approved and not for human or veterinary use, clinical, diagnostic, or therapeutic purposes. By purchasing RUO materials, you confirm they will be handled by qualified personnel in a proper research setting and in compliance with regulations. Products must not be administered to humans or animals or represented as safe or effective for medical use. Use is at your own risk; Direct Doctor Supply assumes no liability for misuse or regulatory issues.

2026 Direct Doctor Supply All rights reserved.
Terms Of Use Privacy Policy Refund and Replacement Shipping & Delivery